Skip to main content
SpringerLink
Log in

Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2

  • Chapter
  • First Online:
Alternative Medicine Interventions for COVID-19

Abstract

Keeping in view the pandemic situation and whose recommendations to search antiviral medicines, biologists, pathologists, and microbiologists started working on that. Chinese government has recommended therapeutic application of traditional Chinese medicine (TCM) against COVID-19 in the third edition of COVID-19 Treatment Guidelines (2020) published in January. From the day onward, hundreds of herbs have been practiced all over China. This chapter has been planned to compile existing information for future utilization of TCM all over the world with better understanding and minimal chances of side effects. For well understanding of TCM as reliable treatment (for COVID-19), it is aimed to pool data of TCM from its history of usage against other viruses and against related viruses of SARS-CoV, collection of the data regarding case studies with positive outcomes, detailed pool of knowledge about most practiced (approved/proposed) decoctions, frequently used components of these decoctions, their active ingredients, possible mechanism to inhibit viruses, similarity of SARS-CoV with SARS-CoV-2, and possibility to treat COVID-19 with antiviral drugs previously used against SARS-CoV. Additional relevant meta-analyses have been reviewed that may guide about practical implementation of these TCM in the future round the globe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Organization, W. H. (2020) Coronavirus disease 2019 (COVID-19): situation report, 72

    Google Scholar 

  2. Commission, N. H. (2020) National Administration of Traditional Chinese Medicine. Diagnosis and treatment program for COVID-19 (trial version 7)

    Google Scholar 

  3. Traditional Chinese Medicine, National Center for Complementary and Integrative Health, Traditional Chinese Medicine: an introduction archived 26 June 2015 at the Wayback Machine

    Google Scholar 

  4. Mahmood S, Parveen A, Hussain I, Javed S, Iqbal M (2014) Possible involvement of secondary metabolites in the thermotolerance of maize seedlings. Int J Agric Biol 16(6):1075–1082

    Google Scholar 

  5. Wink M (2020) Potential of DNA intercalating alkaloids and other plant secondary metabolites against SARS-CoV-2 causing COVID-19. Diversity 12(5):175

    Article  CAS  Google Scholar 

  6. Xiao X-H, Wang J-B, He C-H (2003) On the rational exertion for the prescriptions and drugs of TCM in preventing and treating SARS. Zhongguo Zhong yao za zhi/Zhongguo zhongyao zazhi/China J Chin Mater Med 28(7):664–668

    Google Scholar 

  7. Huang Y-F, Bai C, He F, Xie Y, Zhou H (2020) Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol Res 158:104939

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gelderblom HR (1996) Structure and classification of viruses. In: Medical microbiology, 4th edn. University of Texas Medical Branch at Galveston, Galveston

    Google Scholar 

  9. Yang Y, Islam MS, Wang J, Li Y, Chen X (2020) Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 16(10):1708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280.e8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fu Y, Cheng Y, Wu Y (2020) Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 35(3):266–271

    Google Scholar 

  12. Yang L, Cui H, Liu X, Wen W, Wang H (2020) Feasibility of Xiaochaihu decoction on fever induced by coronavirus disease 2019 (COVID-19) based on network pharmacology. Chin Trad Herbal Drugs 7:1761–1775

    Google Scholar 

  13. Chen C-N, Lin CP, Huang K-K, Chen W-C, Hsieh H-P, Liang P-H et al (2005) Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3′-digallate (TF3). Evid Based Complement Alternat Med 2:209–215

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wen C-C, Shyur L-F, Jan J-T, Liang P-H, Kuo C-J, Arulselvan P et al (2011) Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication. J Tradit Complement Med 1(1):41–50

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ryu YB, Jeong HJ, Kim JH, Kim YM, Park J-Y, Kim D et al (2010) Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorg Med Chem 18(22):7940–7947

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cheng PW, Ng LT, Chiang LC, Lin CC (2006) Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol 33(7):612–616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Loizzo MR, Saab AM, Tundis R, Statti GA, Menichini F, Lampronti I et al (2008) Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chem Biodivers 5(3):461–470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chen C-J, Michaelis M, Hsu H-K, Tsai C-C, Yang KD, Wu Y-C et al (2008) Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. J Ethnopharmacol 120(1):108–111

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kim H-Y, Shin H-S, Park H, Kim Y-C, Yun YG, Park S et al (2008) In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. J Clin Virol 41(2):122–128

    Article  PubMed  Google Scholar 

  20. Ang L, Lee HW, Choi JY, Zhang J, Lee MS. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integrative Medicine Research. 2020 Jun 1;9(2):100407

    Google Scholar 

  21. Hedi H, Norbert G (2004) 5-Lipoxygenase pathway, dendritic cells, and adaptive immunity. Biomed Res Int 2004(2):99–105

    Google Scholar 

  22. Singh NK, Rao GN (2019) Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies. Prog Lipid Res 73:28–45

    Article  CAS  PubMed  Google Scholar 

  23. Xin S, Cheng X, Zhu B, Liao X, Yang F, Song L et al (2020) Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother 129:110500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yang Y, Islam MS, Wang J, Li Y et al (2020) Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 16(10):1708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu N, Li S, Fan K et al (2020) The prevention and treatment of COVID-19 with Qingfei Paidu decoction in shanxi China. TMR Mod Herb Med 3:1–5

    Google Scholar 

  26. Chen H, Xie Z, Zhu Y et al (2020) Chinese medicine for COVID-19: a protocol for systematic review and meta-analysis. Medicine 99(25):e20660

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y et al (2020) Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province. China Chin Med 15:1–13

    CAS  Google Scholar 

  28. Gao K, Song Y-P, Chen H et al (2020) Therapeutic efficacy of Qingfei Paidu decoction combined with antiviral drugs in the treatment of corona virus disease 2019: a protocol for systematic review and meta-analysis. Medicine 99(22):e20489

    Article  CAS  PubMed  Google Scholar 

  29. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP et al (2020) Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China, 2020. Emerg Infect Dis 26(5):1052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sun KB, Zhang XY, Liu J et al (2020) Network pharmacological analysis and mechanism prediction of Xiaochaihu Decoction in treatment of COVID-19 with syndrome of pathogenic heat lingering in lung and obstructive cardinalate. Chin Tradit Herb Drug 51(7)

    Google Scholar 

  31. Miao S, Jialei T, Shaoju X (2020). The molecular mechanism of treating COVID-19 with Huashi Baidu Formula based on network pharmacology. J Chinese Med Mat:1–7

    Google Scholar 

  32. Wang Y, Li X, Zhang JH, Xue R, Qian JY, Zhang XH et al (2020) Mechanism of Xuanfei Baidu Tang in treatment of COVID-19 based on network pharmacology. Zhongguo Zhong yao za zhi/Zhongguo zhongyao zazhi/China J Chin Mater Med 45(10):2249–2256

    Google Scholar 

  33. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S et al (2020) Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 156:104761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Duan C, Xia W, Zheng C (2020) Clinical observation on the treatment of novel coronavirus pneumonia with Jinhua qinggan granules. J Tradit Chin Med:1–5

    Google Scholar 

  35. Mao Y, Su Y, Xue P et al (2020) Discussion on the mechanism of Jinhua Qinggan Granule in the treatment of novel coronavirus pneumonia. J Chin Med Mater 11:2843–2849

    Google Scholar 

  36. Gong PY, Guo YJ, Li XP, et al (2020) Exploring active compounds of Jinhua Qinggan Granules for prevention of COVID-19 based on network pharmacology and molecular docking. Chin Tradit Herb Drug 51(7)

    Google Scholar 

  37. Jimilikhan SMY, Mohammad MN, Ainival W et al (2020) Study on the active components of Jinhua Qinggan Granule in adjuvant treatment of novel coronavirus (COVID-19) based on network pharmacology and molecular docking. J Chin Med Mater (05):1275–1283. (Chinese)

    Google Scholar 

  38. Simayi J, Noormaimaiti M, Wumaier A, Yusufu M, Noor M, Mahemuti N et al (2020) Study on the active components in the adjuvant treatment of novel coronavirus pneumonia (COVID-19) with Jinhua Qinggan granules based on network pharmacology and molecular docking. J Chin Med Mater. http://kns.cnki.net/kcms/detail/44.1286.R.20200323.1926.002.html. [Google Scholar]

  39. Ren Y, Yao MC, Huo XQ, Gu Y, Zhu WX, Qiao YJ et al (2020) Study on treatment of “cytokine storm” by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway. Zhongguo Zhong yao za zhi/Zhongguo zhongyao zazhi/China J Chin Mater Med 45(6):1225–1231

    Google Scholar 

  40. Du H, Wang P, Ma Q, Li N, Ding J, Sun T et al (2020) Preliminary study on the effective components and mechanisms of Huoxiang Zhengqi decoction inhibiting the replication of new coronavirus. Modernization of traditional Chinese medicine and materia materia-world science and technology

    Google Scholar 

  41. Deng YJ, Liu BW, He ZX, Liu T, Zheng RL, Di Yang A et al (2020) Study on active compounds from Huoxiang Zhengqi oral liquid for prevention of coronavirus disease 2019 (COVID-19) based on network pharmacology and molecular docking. Chin Tradit Herb Drug 51(5)

    Google Scholar 

  42. Li Q, Wang H, Li X, Zheng Y, Wei Y, Zhang P et al (2020) The role played by traditional Chinese medicine in preventing and treating COVID-19 in China. Front Med 14(5):681–688

    Google Scholar 

  43. Wang Y, Ma J, Wang S, Zeng Y, Zhou C, Ru Y et al (2020) Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19. Eur Rev Med Pharmacol Sci 24(6):3360–3384

    PubMed  Google Scholar 

  44. Liang F, Dong L, Zhou L et al (2020) Traditional Chinese medicine for symptoms of upper respiratory tract of COVID-19: a protocol for systematic review and meta-analysis. Medicine 99(30):e21320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ye CH, Gao MN, Lin WQ, Yu KQ, Li P, Chen GH (2020) Theoretical study of the anti-NCP molecular mechanism of traditional Chinese medicine Lianhua-Qingwen Formula (LQF). Polar 2(21.52):10–68

    Google Scholar 

  46. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Shi Y, Wei J, Liu M, Jin X, Zhou H, Zhu W et al (2020) Study on the overall regulation of Xuebijing injection in treating corona virus disease 2019. Shanghai J Tradit Chin Med 54:1–7

    Google Scholar 

  48. He T, Duan C, Li X et al (2020) Potential mechanism of Xuebijing injection in treatment of coronavirus pneumonia based on network pharmacology and molecular docking. Chin J Mod Appl Pharm 37(4):398–405

    Google Scholar 

  49. Kong Y, Lin LL, Chen Y et al (2020) Modernization of traditional Chinese medicine and materia medica-world science and technology. Exploring the mechanism of Xuebijing injection in treating COVID19 based on network pharmacology. http://kns.cnki.net/kcms/detail/11.5699.r.20200411.2157.008.html. [Google Scholar]

  50. Commission, G. O. o. t. N. H. (2020) Office of the State Administration of Traditional Chinese Medicine. Notice on printing and distributing the diagnosis and treatment program of new coronavirus pneumonia (trial seventh edition). Medical letter of the state health office(184)

    Google Scholar 

  51. Sun X, Zhang Y, Liu Y et al (2020) Study on mechanism of Reduning Injection in treating novel coronavirus pneumonia based on network pharmacology. J Chin Med Mater:1–9

    Google Scholar 

  52. Shen F, Fu Z, Wu Y, Kuang G, Li L, Zhu K et al (2020) The potential targets and mechanisms of Shufeng Jiedu Capsule for novel coronavirus pneumonia (COVID-19) based on network pharmacology and molecular docking. Guiding J Tradit Chin Med Pharm 26(5):8–15

    Google Scholar 

  53. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X et al (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63(3):457–460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Cao C, Cui Y, Chu Y-X, Shi Y-Y, Wu X-H, Wang X-Y et al (2020) Investigation on mechanism and active components of Shufeng Jiedu Capsule in treatment of COVID-19 based on network pharmacology and molecular docking. Chin Trad Herbal Drugs 51:2283–2296

    Google Scholar 

  55. Fu Y-J, Yan Y-Q, Qin H-Q, Wu S, Shi S-S, Zheng X et al (2018) Effects of different principles of traditional Chinese medicine treatment on TLR7/NF-κB signaling pathway in influenza virus infected mice. Chin Med 13(1):42

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46(4):586–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Wu H, Wang J, Yang Y, Li T, Cao Y, Qu Y et al (2020) Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology. Acta Pharm Sin 55:374–383

    Google Scholar 

  58. Fan AY, Gu S, Alemi SF (2020) Chinese herbal medicine for COVID-19: current evidence with systematic review and meta-analysis. Integr Med 18(5):285–394

    Google Scholar 

  59. Lestari K, Sitorus T, Instiaty SM et al (2020) Molecular docking of quinine, chloroquine and hydroxychloroquine to angiotensin converting enzyme 2 (ACE2) receptor for discovering new potential COVID-19 antidote. J Adv Phar Educ Res|Apr–Jun 10(2):1–4

    CAS  Google Scholar 

  60. Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV (2002) Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 76(22):11440–11446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Wink M, Schmeller T, Latz-Brüning B (1998) Modes of action of allelochemical alkaloids: interaction with neuroreceptors, DNA, and other molecular targets. J Chem Ecol 24(11):1881–1937

    Article  CAS  Google Scholar 

  62. Wink M (2007) Molecular modes of action of cytotoxic alkaloids: from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance. Alkaloids Chem Biol 64:1–47

    Article  CAS  PubMed  Google Scholar 

  63. Jin XJ, Guan RN, Mao JJ et al (2020) Exploration on material basis of Qingfei Paidu Decoction with multi-target system against COVID-19 based on CADD. Chin Tradit Herb Drugs 51:1984–1995. (Chinese)

    Google Scholar 

  64. Choy K-T, Wong AY-L, Kaewpreedee P, Sia S-F, Chen D, Hui KPY et al (2020) Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 178:104786

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282(28):20059–20063

    Article  CAS  PubMed  Google Scholar 

  66. Ruan Q, Yang K, Wang W et al (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46(5):846–848

    Article  CAS  PubMed  Google Scholar 

  67. Zhao J, Tian S-S, Yang J et al (2020) Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network pharmacology. Chin Trad Herbal Drugs 51:829–835

    Google Scholar 

  68. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 395(10223):497–506

    Article  CAS  Google Scholar 

  69. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)

  70. Chen Q, Liu J, Wang W, Liu S, Yang X, Chen M et al (2019) Sini decoction ameliorates sepsis-induced acute lung injury via regulating ACE2-Ang (1-7)-Mas axis and inhibiting the MAPK signaling pathway. Biomed Pharmacother 115:108971

    Article  PubMed  Google Scholar 

  71. de Kloet AD, Krause EG, Woods SC (2010) The renin angiotensin system and the metabolic syndrome. Physiol Behav 100(5):525–534

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. He LL, Gong PY, Feng Y et al (2020) Analysis on the application of Traditional Chinese Medicine in the treatment of COVID-19 by suppressing cytokine storm. Chin Tradit Herb Drug 51:1375–1385. [Google Scholar]

    Google Scholar 

  73. Yan B, Tian G (2017) Renin-angiotensin system and diabetic cognitive dysfunction, and effects of traditional Chinese medicine on Them. Chin J Rehab Theory Pract 23(3):270–273

    CAS  Google Scholar 

  74. Zhou J, Yang M, Zhang Z et al (2020) Mechanistic investigation of multiple organ dysfunction syndrome induced by 2019 novel coronavirus. Chin J Mult Organ Dis Elderly 19:226–228. [Google Scholar]

    Google Scholar 

  75. Chen MJ, Gao L, Tong ZQ. Network pharmacology study on screening of effective Chinese medicine for treatment of novel coronavirus pneumonia based on renin-angiotensin system. Chin Tradit Herbal Drugs. 2020. http://kns.cnki.net/kcms/detail/44.1286.R.20200326.1618.004.html. [Google Scholar]

  76. Xu JH, Xue Y, Zhang W et al (2020) Study on mechanism of Shufeng Jiedu Capsule in treating COVID-19 based on network pharmacology. Chin Tradit Herb Drug 51:2015–2023. [Google Scholar]

    Google Scholar 

  77. Han L-W, Zhang Y-G, Li H-N, Wang H-Y, Li X-B, Wang X-J et al (2020) Network pharmacologic molecular mechanism of Shenmai Injection in treatment of COVID-19 combined with coronary heart disease. Chin Trad Herbal Drugs 9:2334–2344

    Google Scholar 

  78. Blanco-Melo D, Nilsson-Payant BE, Liu W-C et al (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036–1045.e9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Xia J, Rong L, Sawakami T, Inagaki Y, Song P, Hasegawa K et al (2018) Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma. Biomed Pharmacother 99:921–930

    Article  CAS  PubMed  Google Scholar 

  80. Zimmermann C, Krämer N, Krauter S, Strand D, Sehn E, Wolfrum U, Freiwald A, Butter F, Plachter B (2020). Autophagy interferes with human cytomegalovirus genome replication, morphogenesis, and progeny release. Autophag 2:1–7

    Google Scholar 

  81. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720

    Article  CAS  PubMed  Google Scholar 

  82. Hu W, Feng Z, Levine AJ (2012) The regulation of multiple p53 stress responses is mediated through MDM2. Genes Cancer 3(3–4):199–208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Tao Q, Du J, Li X, Zeng J, Tan B, Xu J et al (2020) Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm 46(8):1345–1353

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Wauters E, Van Mol P, Garg AD, Jansen S, Van Herck Y, Vanderbeke L et al (2020) Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. BioRxiv

    Google Scholar 

  85. Hoxha M (2020) What about COVID-19 and arachidonic acid pathway? Eur J Clin Pharmacol 76(11):1501–1504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Müller C, Hardt M, Schwudke D, Neuman BW, Pleschka S, Ziebuhr J (2018) Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture. J Virol 92(4)

    Google Scholar 

  87. Lipfert P, Seitz R, Arndt JO (1987) Studies of local anesthetic action on natural spike activity in the aortic nerve of cats. Anesthesiol J Am Soc Anesthesiol 66(2):210–213

    CAS  Google Scholar 

  88. Harvey RD, Morgan ET (2014) Cancer, inflammation, and therapy: effects on cytochrome P450–mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther 96(4):449–457

    Article  CAS  PubMed  Google Scholar 

  89. El-Ghiaty MA, Shoieb SM, El-Kadi AO (2020) Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms. Med Hypotheses 144:110033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C et al (2007) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62(6):635–641

    Article  CAS  PubMed  Google Scholar 

  91. Sun CY, Sun YL, Li XM (2020) The role of Chinese medicine in COVID-19 pneumonia: a systematic review and meta-analysis. Am J Emerg Med 38:2153–2159

    Google Scholar 

  92. Chi X, Wang S, Baloch Z, Zhang H, Li X, Zhang Z et al (2019) Research progress on classical traditional Chinese medicine formula lily bulb and rehmannia decoction in the treatment of depression. Biomed Pharmacother 112:108616

    Article  PubMed  Google Scholar 

  93. Zhang B, Zhang K, Tang Q, Sun K, Han Z (2020) Acupuncture for breathlessness in COVID-19: a protocol for systematic review and meta-analysis. Medicine 99(27):e20701

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Zhu Y, Jiang Z, Zhang Y, Zhang Q, Li W, Ren C, Yao R, Feng J, Ren Y, Jin L, Wang Y (2020) Assessment of Chinese medicine for coronavirus-related pneumonia: a protocol for systematic review and meta-analysis. Medicine 99(24):e20613. https://doi.org/10.1097/MD.0000000000020613

Download references

Author information

Authors and Affiliations

  1. Department of Botany, Government College University Faisalabad, Faisalabad, Punjab, Pakistan

    Saqib Mahmood, Naeem Iqbal & Samina Sabir

  2. ABWA Hospital & Research Centre, Faisalabad, Pakistan

    Tariq Mahmood

  3. Department of Biochemistry, Government College University, Faisalabad, Pakistan

    Sadia Javed

  4. Office of Research, Innovation and Commercialization, Lahore College for Women University, Lahore, Pakistan

    Muhammad Zia-Ul-Haq

Authors
  1. Saqib Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tariq Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naeem Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samina Sabir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sadia Javed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Muhammad Zia-Ul-Haq
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lahore College for Women University, Lahore, Pakistan

    Muhammad Zia-Ul-Haq

  2. Biology Department, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

    May Nasser Bin-Jumah

  3. Biology Department, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

    Sarah I. Alothman

  4. Health Sciences Research Centre, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

    Hanan A. Henidi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mahmood, S., Mahmood, T., Iqbal, N., Sabir, S., Javed, S., Zia-Ul-Haq, M. (2021). Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2. In: Zia-Ul-Haq, M., Bin-Jumah, M.N., Alothman, S.I., Henidi, H.A. (eds) Alternative Medicine Interventions for COVID-19. Springer, Cham. https://doi.org/10.1007/978-3-030-67989-7_3

Download citation

Publish with us

Policies and ethics

Search

Navigation